A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

Trial Profile

A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Abemaciclib (Primary) ; Loperamide; Tamoxifen
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms nextMONARCH 1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 10 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.
    • 11 Apr 2017 Planned End Date changed from 1 Aug 2019 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top